In 2013, the Pacific Cancer Research Consortium (PCRC) was created to bring clinical trials and cancer care delivery research to community cancer treatment centers in the Western United States as an NCI Community Oncology Research Program (NCORP) Community Site. Under a multiple PI/PD structure, the 3 primary component sites?Swedish Cancer Institute in Seattle, Providence Portland Medical Center in Portland, and Mountain States Tumor Institute in Boise?have facilitated the conduct of NCORP-sponsored trials at more than 40 affiliate sites in Alaska, Washington, Oregon, Idaho, Montana, and California. Over the past 5 years, the PCRC built on its collective experience in clinical research, its shared organizational structure, and its diverse community demographics to achieve the research and accrual goals of the initial round of funding. As an established NCORP Community Site, for the next round of funding, the PCRC will continue to ?bring cancer clinical research studies to individuals in their own communities? by (1) developing clinically important trials and achieving robust accruals that focus on underrepresented populations, (2) participating in cancer treatment, cancer control and prevention, cancer care delivery research, screening, and imaging trials proposed by the NCORP Research Bases, (3) optimizing and streamlining procedures to ensure timely and accurate data submission and specimen collection, (4) enhancing the participation of minorities and underserved populations by involving patient advocates, and (5) mentoring the next generation of community-based cancer clinical trialists.
(RELEVANCE) The NCORP Community Site outlined in this continuation application comes from our experience building a multicenter infrastructure in the Western United States that excels in patient accrual and fosters new and close collaboration between investigators. We believe that our structure will accelerate the translation of knowledge gained from trials in cancer treatment, cancer control and prevention, cancer care delivery research, screening, and imaging into clinical practice and thereby enhance the science, the treatments, and the delivery of care to patients with cancer in community settings.
|Mongiovi, Jennifer M; Zirpoli, Gary R; Cannioto, Rikki et al. (2018) Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221). Breast Cancer Res 20:146|
|Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888|
|Smith, Eileen P; Li, Hongli; Friedberg, Jonathan W et al. (2018) Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). Biol Blood Marrow Transplant 24:700-707|
|West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92|
|Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332|
|Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504|
|Lemieux, Julie; Brundage, Michael D; Parulekar, Wendy R et al. (2018) Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. J Clin Oncol 36:563-571|
|Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493|
|Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703|
|Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522|
Showing the most recent 10 out of 33 publications